Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Citations Over TimeTop 1% of 2004 papers

Abstract

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

Related Papers

• → Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant(2006)58 cited
• → Erythroid Induction of Chronic Myelogenous Leukemia K562 Cells Following Treatment with a Photoproduct Derived from the UV‐A Irradiation of 5‐Methoxypsoralen(2010)7 cited
• Synthesis of C-Nucleoside Analogues： 2-[2-（Hydroxymethyl）-1, 3-dioxolan-5-yl]1, 3-thiazole-4-carboxamide and 2-[2-（Mercaptometh-yl）-1, 3-dioxolan-5-yl] 1, 3-thiazole-4-carboxamide(2004)
• Development of An ssDNA Aptamer-based Test Method for Chronic Myelogenous Leukemia K562 Cells(2011)
• Study on the expression of Smad7 in human chronic myelogenous leukemia cell line( K562)(2005)